Abstract Background Producing an appropriate number of engineered cells is considered as one of the influential factors in the successful treatments with chimeric antigen receptor (CAR) T cells. To this aim, the transduction rate of the viral vectors can play a significant role. In addition, improving transduction rates can affect the success rate of this treatment due to hard-transduced T lymphocytes. Results In this study, activated T cells were transduced using different transduction methods such as spinoculation, retronectin, polybrene, spinoculation + retronectin, and spinoculation + polybrene after selecting the most efficient transfection method to produce recombinant viral particles containing MUC1 CAR. PEI and lipofectamine with th...
Background Chimeric antigen receptor (CAR) T cells have shown considerable promise as a personalized...
Background Adoptive cell therapy with chimeric antigen receptor T cells (CAR-T) has become a standar...
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own imm...
<h3>Chimeric antigen receptors (CARs) are genetically delivered fusion molecules that elicit T-cell ...
Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive clinical responses in patie...
The efficient expression of T-cell receptors (TCRs) or chimeric antigen receptors (CARs) in primary ...
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremen...
Breast cancer is one of the most common malignancies among woman. Decades of scientific study have l...
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremen...
Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematologi...
Background For our clinical immunogene therapy study for the treatment of renal cell carcinoma (RCC)...
Lentiviral vectors (LVs) are potent tools to genetically modify hematopoietic stem cells (HSCs), T c...
Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody ...
Anti-CD19 chimeric antigen receptor (CAR)-T cells have achieved impressive outcomes for the treatmen...
Redirected T cells genetically modified with a chimeric antigen receptor (CAR) have induced spectacu...
Background Chimeric antigen receptor (CAR) T cells have shown considerable promise as a personalized...
Background Adoptive cell therapy with chimeric antigen receptor T cells (CAR-T) has become a standar...
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own imm...
<h3>Chimeric antigen receptors (CARs) are genetically delivered fusion molecules that elicit T-cell ...
Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive clinical responses in patie...
The efficient expression of T-cell receptors (TCRs) or chimeric antigen receptors (CARs) in primary ...
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremen...
Breast cancer is one of the most common malignancies among woman. Decades of scientific study have l...
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremen...
Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematologi...
Background For our clinical immunogene therapy study for the treatment of renal cell carcinoma (RCC)...
Lentiviral vectors (LVs) are potent tools to genetically modify hematopoietic stem cells (HSCs), T c...
Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody ...
Anti-CD19 chimeric antigen receptor (CAR)-T cells have achieved impressive outcomes for the treatmen...
Redirected T cells genetically modified with a chimeric antigen receptor (CAR) have induced spectacu...
Background Chimeric antigen receptor (CAR) T cells have shown considerable promise as a personalized...
Background Adoptive cell therapy with chimeric antigen receptor T cells (CAR-T) has become a standar...
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own imm...